today. as everyone Susie. you, Thank as and I you Thank healthy joining for you your well COVID-XX braving and the pandemic to us are possible. hope families that
see who honored and us I I'm crisis to We're of COVID-XX to helping amid employees be humbled able employees day community stronger emerge across the our are be truly of Boston the continue resilience the our patients, every pandemic. customers, part and globe, to the serve navigate to on as Scientific side. to other
informed, consistent providing take to support customers our operations. values, employees and patient our core keeping with is focus Our while managing and actions to safe effectively communicate and transparency with
our acting customers capabilities while position. our expanded to with enable cash sales fast We've our also We're clinical and support, partnering education, recovery, enablement and expenses physician preserving also digital reduce training. in a virtual operational remote to
as to We as preserve strategic actions jobs have immediate taken goal possible. programs many these and with the
face well respirator, of technologies, our and countermeasure developed also to weeks, personal capability protective was shields in just as personal the as four develop such equipment. donations and We've Coventor leveraged approved as which
of comments impact my now of we'll I'll on XXXX quarter the provide COVID-XX. first and some most highlights on focus
XXXX commitments launches. geographic to and teams the guidance specific along and with key long-term sales insights offer highlight continue wrap will dedication then our with our into providing not While we're recent innovation I'll and some this their up to we as businesses at and EPS sustainability segments, communities. environment revenue trends some point, updates and our
For X.X% down operational an the X%, with pre-announcement. X% X% XXXX, up up the basis, with and US reflecting in sales from Asia-Pac COVID-XX company X.X% April first impact on an EMEA total basis, sales operationally. of declined grew line quarter Total organic and X on our
growth X%, both tracking down Sales interventional with down mid-March. sales are first before in by quarter rhythm These endo up cardiovascular neuro kicked X%, up sales low-single significant interventions MedSurg organically. negative both were X%, February health in and segment, cardiology cardiovascular, to expectations was digit X%. January in led in and our then our results uro/pelvic declined Within peripheral were and segments trends
points BTG by PI, XXX basis led quarter. grew within company TheraSpheres to mid-teens interventional medicines in growth, contributed total the which Operationally
rhythm of pharma ahead sales EP million sales XX with contributed $XX operationally, XXX company a neuro, did up specialty Vertiflex. declined basis In total and contribution X% X%. was dropped neuromodulation company forecast to declined points XX%, from sales to CRM X% grow And and Neuromod and points growth. basis
levels Despite to challenge overall decline the margin costs, led a is versus down XXX and XX.X%, taking basis adjusted sales actions P&L adjusted to for fell QX a immediate operating the EPS which XX% to lower $X.XX, points reduce of XXXX. year-over-year, quarter as
the rest outlook to of for turn to Now year. the
revenue of deferrals see to started significant all to I QX and in expectations across result were those a mid-March our in mentioned, European businesses. until US tracking geographies of when as As we declines sales procedure
QX. global revenue the QX, COVID-XX second to weeks of toughest month trends April April down And Generally, XX%. impact with for be We're those most the planning expect to April. three first half XX% approximately the of negative in continued March currently we of the month of the have within negative for in in significant
in the XX% the weeks down Through of Middle Asia-Pac, prior a Africa, Europe, From we XX% regional see trended results down versus three recovery. of results US in year. down based regional XX% on East perspective, varying the first April, sales different have East, in and phases
sales as recent have degrees, with to varying quarter. year-over-year sales reopen results very throughout begun down in significantly net the a facilities, for improvement some seen some still sequential to anticipate procedures. we've We Importantly, second QX, slight elective trends April improvement for but monthly
We there QX in also basis, from rates on contract aim then, to And are growth but we will QX, likely revenue obviously still return of decline. a year-over-year expect uncertainties. but QX to improve many
improves. Despite soon pipeline launches as remain the now procedure volume impact the poised several from recent with for broader the across businesses ongoing our approvals COVID-XX, global strong, commercialization very environment as and
which I'll which that elective to also product lines days, to to provide along weeks, in measured framed in trends from We've measured urgency major in with in product procedural the conditions spectrum elective, April. on color is and hours emergent, generally cross emergent, is semi relatively our measured we across several that And acuity, is deferred over months. note of have be which can't categories, for thus including periods. those treat families levels and extended majority are high of
of of procedures estimating of recovery, site physician consideration. is elective the inpatient a societies overall the enable for addition, important In to pace restart And before outpatient when guidelines procedures. service recent from an range reopening
Please details physician two-thirds our the to service slide of was XXXX XX office to inpatient Relations business, one-third on setting centers. spans of hospital ambulatory Site commentary. outpatient, our website US outpatient. data, by across two-thirds outpatient varies and approximately Investor but, within refer labs and XXXX the surgery mix The based for Medicare supporting split revenue overall, claims
and weeks April by a urology year, We of on procedures, down of franchises. such versus XX% sales playing SpaceOAR recent the health, Tria prostate deferrable for For health, the through pelvic uro/PH believe US recovery of trends launch products our first high office curves higher stone the our the mix Europe. as ASE in mix have the were the given prosthetic most from stents and roughly procedures, franchise with one showing well pressure better elective specific of products as urology/pelvic our resilience and and may faster as three key prior role, the more aided a potential floor
LithoVue, single scopes. the of is use And ureteroscope, and environment utility single speed benefit the could use as supports which current our
in also for an NCCN recovery hydrogel is the for spacing will patients included guidelines. be technology prioritized as important is and treatments SpaceOAR now cancer
which Rezūm, entirely In the data which rate years an through procedure, five clinical office-based five-year recently surgical was retreatment BPH, is reported in X.X%.
it Rezūm's XX.X% and published Technology. competitive retreatment rate for unchanged of MIS to Importantly, data, results this from a is the four-year compares
uro/PH our commercialized divest multiple investment and within priorities strategic the to today Surgical. opportunities to health announcing broad we're that agreement portfolio given portfolio, the intrauterine Minerva Finally, a definitive reached we've
In ovarian we cancer addition, potential stop we've is made to near additional nVision the in acquired work decision, a for Cytuity for XXXX. at least that R&D term, for the platform diagnosis or clinical from Cytuity. funding
the establish realize current for cost risk, practical well we potential for the landscape our detection and extended a clinical need have evidence as as product commercial horizon while ovarian of utility who to necessary of the view the recognize of improved strong time options to high have safely Unfortunately, women cancer the reimbursement the Cytuity.
are higher year-over-year, non-deferrable procedures XX% to within business. Turning MedSurg reflecting month-to-date trends endoscopy, down a mix April our of
procedures ERCP bile ducts are deferrable. pancreas the and for
longer However, procedures. biopsies related patients four other six and to wait tumor for can't typically weeks removal, stone than
infection to D COVID of And restricted prevention certainly continue and represent use market for single we believe albeit to single capacity. emphasizes EXALT hospital scopes, portfolio multi-billion and scopes over a need the due opportunity In progressing, dollar imaging our is launch access time. therapeutic that the the slowly pandemic use current
a in this CE next US half second franchise, approval clearance and a launch. also received toward in We're pleased early global that scope the working April, SpyGlass we're Discover and Mark
for Also stem hemostasis on XXX for track our in FDA and WallFlex QX. April, approval Ultra next duodenal colonic systems soft clip we in Res and clearance the generation remains received
year-over-year, And implants and the higher urgently replacements non-deferrable from are block of down heart and to reflects slightly Turning of those mix a more slightly approximately who holding up with April need XX% ICDs. brady than better sales including replacements. in pacers, de majority CRM, procedures novo suffering this patients and
In of and secondary therapy, non-deferrable CRT-D a and including ICD replacements. prevention, defibrillators, procedures, subset
as CRM lead by HeartLogic launches service INGEVITY+ led be offerings. as will S-ICD US and ongoing the replacements programmer well our remote with XXXX of recovery
clearance FDA Importantly, we monitor. of expect and LUX-Dx cardiac mid-year our implantable to continue launch
virtual late UNTOUCHED trials, global CRM support which PRAETORIAN forward to the We should two also look the franchise. to of in our HRS our growth breakers and continue S-ICD franchise,
with Electrophysiology double-digit has of mix in highly and are approximately arrhythmias year-over-year, down considered franchise XX% sales percentage April in a as higher a CRM low this unstable non-deferrable. symptomatic deferrable
is catheter portfolio, our labs be will strengthening European EP when access shot generation will a POLARx, which cryoablation Our recovery resume that second QX launch improves. in by its including single to driven
around the of impedance delivery approval which RF via received effect in changes energy monitors local the catheter tip, DIRECTSENSE, mid-April. in
also QX therapeutic stable four-sensing in approval point our catheter. anticipate Europe for We
the in and SCS for year, DBS neuromodulation, a XX% very seen first April three sales the elective In procedures. decline of given versus deferability of prior high weeks have of rates
were that offset to competencies to ready physicians this, So, connectivity to leverage resume. we as patients digital our with to continue serve them maintain and procedures
that experience the ASC, ASC implanting procedures procedures than majority occur of to hospital trial all a is office we in Given physicians SCS an that which will have believe likely the many SCS XXX% based. and an or and DBS, typically earlier faster recovery setting, access
coronary cardiology, and Similarly, non-deferrable with April are of prior procedures which trending year within WATCHMAN. sales sales heart heart, structural higher deferrable than impacted, a XX% versus about TAVR less generally down more For procedures therapies. mix more structural sales interventional resilient with reflects are therapy coronary
pose deferrable decline mix of And future this the franchises, near as believe in and recovery emergent as significant relatively curve but mortality. terms the sales We April our be drive one in or overall, the procedures. highest morbidity term, that IC threat of acute for will procedures low reflects a may both
platform eight we're XXXX, to to major highlighted our our enhancements our XXmm, planning and coronary in and our MEGATRON two therapy launches SYNERGY SYNERGY markets by enhancements later for PCI atherectomy across XD, guidance SYNERGY platform. ROTABLATOR Importantly,
that the proud as also in more We're this neoX approval healthcare resume of release begin achieved of Mark plan the to and limited month a a systems we ACURATE CE regular very cadence market team earlier our procedures. TAVR Europe,
procedure US of travel volumes. ongoing Similarly, delivery training, look LOTUS in of we COVID-XX recovery restrictions the and proctor Edge the forward but limit to Japan has by the and launch and do the that been challenged
second continue HRS PINNACLE results the XXXX presentation of [indiscernible] half late to for plan of WATCHMAN FLX also US We a May at breaking launch in trial. clinical FLX an
this are we've physician therapy be capacity that based And rescheduled an and/or although WATCHMAN on And surveyed will when for seeking eligible procedures increased their need to thinners. deferrable, are protocols procedures. patients alternative are postponed confident allowed operators blood procedures facility for elective largely
revenue of Arterial, lowest date to mix highest deferrable the procedures April interventions, peripheral and mix to XX% order Turning by down non-deferrable ranges procedures. deferrable of venous interventional approximately to to oncology, therapy is and in estimated of category.
coming China. launches balloon launches and product China a Athletis Ranger along this DES in we cadence strong the a ELUVIA with had We US in arterial, in plan PI of launch for business. DCB In of
In and anticipate controller XXXX. Also, the and Clothunter IVUS for system VICI EKOS new venous, the for a will AngioJet for WALLSTENT we venous all in for stent catheter. new deployable Verto a reverse received approval approval indication the and thrombectomy system be launched the
In and the catheter. to interventional microwave launch oncology, we HeatFX system new plan microwave TruSelect the ablation
very pipeline in XXXX. rich in So, a PI of launches
by turning learned lessons our in team. X% which driven now from and to Japan, Asia in sales region by and growth Zealand. Australia were QX declines mainly declined China So, year-over-year, partially offset in the New Korea,
continue past in $XX we peak was see the China, week estimate And government procedures In we to million that on country the the XX is to since close announced China. impact the March each to of in quarter. COVID-XX epidemic, first that improvements the the
are procedures could interprovincial starting of to helping restored. from COVID-XX this patient travel, citing lower patient are flow physicians recover and And patient Leading that related city from bans elective tier concerns hospitals deferral is as lift cities is outnumber deaths. also deaths now on larger
case including team's QX. above pre and leveraging engagement QX and online seminars China that could overall, in remote we experience, recover back be believe potentially via And customer its in support. We're China to the trajectory plan COVID-XX hospital
has DCB, In less in LOTUS XD XXXX. uncertain. been launching Our second year-to-date, Japanese the business to look but forward and Japan, impacted of remains Edge half we SYNERGY Ranger
balance the sheet. So, turning to
liquidity we cutting on position And preservation As liquidity. as as details commentary we provide billion recent our Dan are strong a we near-term week, and more believe cost deal, transaction over that $X.X with bank announced in in resulting cash in last will initiatives. on well our the
approximately the delay trial deferral a in clinical enrollments, with months. expect Consistent witnessed and our procedures, of elective of slowdown many clinical thus of six would ongoing we've to a timelines
one quarterly We're product earnings summary quarter, decks, a but temporarily will also calls. deck. page provided future the at suspending XX financial the new important our XXXX highlights this pipeline our of chart Instead reinstate on have to update in our our of of we launches
XXXX to the combines sustainability report, like our performance pledge goals. updates of on financial neutral also carbon XXXX disclosures release highlight online which our with integrated our our I'd and diversity report, inclusion on reporting
company purchase announcement the XXXX. toward this that Recall finalized importantly, is to that, XXXX, a carbon in neutrality medical operations. week's significant by last Boston to US XX-year we've pledge first Scientific XXX% provide we being for made our the device step progress virtual renewable our And have energy with solar power latest was deal which energy goal, first purchase agreement, electricity
doubled since of renewable to percent nearly greenhouse and We've alone tons in of from XX,XXX certified than reduction use emissions XX%, more gas XXXX energy sources XXXX. achieved a of the
landfill all solid and sites We in rate avoidance. XX% of XX% recycle waste manufacturing of a
Scientific. So, at in Boston our proud closing, I'm team incredibly of
portfolio strategy and across diversified in rate fundamentals Our outlook pipeline, long-term people, given category and our high our markets. strong acuity our our remain of our leadership
commitment commitment, selflessness spirit emerge recovery workers their stronger the the to like our like during winning frontline and for I'd thank to also dedication I'd and post employees and COVID. this their for to unwavering time. thank
I'll over Dan. the Now, call to turn
